Epidemiological Study to Evaluate Personality Disorders in Prison Populations in Treatment for Hepatitis C

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

263 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-12-31

Study Completion Date

2013-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Primary objective: Evaluate the prevalence of personality disorders in patients starting treatment for hepatitis C in the prison and determine their influence on the evolution of the disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Novel Hepatitis c micrOelimination Program in Non imprisonEd SenTenced With Alternative Measures

NCT03932396

Hepatotropic Virus Infection Addictive Behaviours o Conducts Mental Disease +1 more

UNKNOWN

Hepatitis C in Severe Mental Disorders: Nursing Programme

NCT04891445

Hepatitis C Severe Mental Disorder

COMPLETED NA

Epidemiological Study to Evaluate the Management of Patients With Chronic Hepatitis C and Previous Treatment Failure

NCT01033045

Hepatitis C

COMPLETED

Telemedicine for Linkage to Care People Who Injected Drugs With Hepatitis C

NCT04035980

Hepatitis C Virus Infection

UNKNOWN NA

A Trial to Reduce Hepatitis C Among Injection Drug Users - 1

NCT00218192

HCV Negative Status HCV Risk Behavior

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Secondary objectives:

* Describe the management of patients with personality disorders on treatment for hepatitis C in the prison.
* Describe the characteristics of patients who discontinue the treatment and the reasons for stratifying by the presence of personality disorders.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis C, Chronic Personality Disorders in Prison

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pegasys, injection subcutaneous

Hepatitis C Virus (HCV) patients monoinfected or coinfected, all genotypes, treatment naive to Peginterferon alfa-2a and Ribavirin (RBV)

Peginterferon alfa-2a

Intervention Type OTHER

Treatment as usual clinical practice

Ribavirin

Intervention Type DRUG

Treatment as usual clinical practice

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Peginterferon alfa-2a

Treatment as usual clinical practice

Intervention Type OTHER

Ribavirin

Treatment as usual clinical practice

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Pegasys Copegus

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients 18 years of age.
* Patients with expected prison stay beyond the duration of follow-up period of the study.
* Patients with chronic HCV infection and detectable viral load to initiate treatment with standard therapy.
* Patients their written informed consent to participate in the study.

Exclusion Criteria

* Patients previously treated with Interferon (IFN) and Ribavirin (RBV).
* Patients can not read or understand a written questionnaire at the discretion of the investigator.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No